Public Release: 

General tumor marker test now offered by GenWay clinical laboratory

General tumor test validated and now available through physician

GenWay Biotech

(San Diego, CA) August 21, 2009 - GenWay Clinical Laboratory, a US-based diagnostic company with CLIA certification, has validated a general tumor marker test in their laboratory and now offers this testing service. This is an ELISA-based assay which simply requires a small blood sample from the patient in order to quantify the amount of the tumor marker in their serum. This unique and proprietary test formula detects and quantifies specific biomarkers, tumor fibrin and fibrinogen degradation products (tFFDP), which are by-products of cancer cells. Elevated tFFDP levels have been associated with at least 14 different cancer types including lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, brain and pancreatic cancer making it one of the most versatile cancer biomarkers available. GenWay is continuing to evaluate the use of this test in other applications. This general tumor marker test can identify elevated levels of tFFDP in a patient which could potentially correspond to the presence of a malignant tumor.

###

For more information about ordering this tumor biomarker test or other CLIA services offered by GenWay Clinical Lab, please visit: www.genwaycliaservices.com. In addition, please email your questions to cliaservices@genwaybio.com.

About GenWay:

GenWay Clinical Laboratory is a subsidiary of GenWay Biotech, Inc., a diagnostic company based in San Diego, CA that manufactures and supplies key components of diagnostic kits, such as antibodies and antigens. The Company's proprietary technology platform specializes in producing avian IgY antibodies from proteins of human, animal, plant, bacterial and other sources. GenWay also offers single chain recombinant scFv and shark vNAR antibody technologies. More than 40,000 products are available from the Company's catalog. GenWay is also actively developing novel diagnostic tests in the field of cancer and STD diagnostics.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.